Senores Pharmaceuticals IPO
Senores Pharmaceuticals IPO is listed on BSE and NSE, priced at ₹372–₹391 per share. The stock debuted at ₹600, delivering a listing gain of 53.5%. The IPO had a lot size of ₹38 shares and a minimum investment of ₹14,858.
Senores Pharmaceuticals Limited IPO
- IPO Dates
- Dec 20, 2024 – Dec 24, 2024
- Price band
- ₹372-391 per equity share
- Minimum Investment
- ₹14,858
- Issue size
- ₹582.11 Cr
- Lot size
- 38
- Allotment Date
- Dec 26, 2024
- Listing
- Dec 30, 2024
- Listing At
- BSE, NSE
IPO timeline
-
Dec 20, 2024
Open Date
Completed
-
Dec 24, 2024
Close Date
Completed
-
Dec 26, 2024
Allotment Date
Completed
-
Dec 30, 2024
Listing Date
Completed
Price Summary
- Last closing
- 960.00 (145.52%)
- 52 week high
- 990.55
- 52 week low
- 491.00
- Last update
Senores Pharmaceuticals IPO Essentials
Senores Pharmaceuticals IPO Details
Senores Pharmaceuticals IPO is priced at ₹372-391 per share with a total issue size of 582.11 crore. The IPO has a lot size of 38 shares and is listed on BSE and NSE.
- Issue price
- ₹372-391 per equity share
- Lot size
- 38 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- Total ₹582.11 Cr :
#Fresh Issue : 1,27,87,723 shares(aggregating up to ₹500.00 Cr) +
#OFS : 21,00,000 shares of ₹10(aggregating up to ₹82.11 Cr) - Total issue size
- 1,48,87,723 shares
(aggregating up to ₹582.11 crore) - Fresh issue
- 1,27,87,723 shares
(aggregating up to ₹500 crore) - Offer for sale (OFS)
- 21,00,000 shares
(aggregating up to ₹82.11 crore) - Listing at
- BSE, NSE
- List price
- 600.0(NSE)
- Listing date
- Registrar
- Link Intime India Private Ltd
- Lead manager
-
Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited
Market Lot Size
Investors can bid for a minimum of 38 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 38 | ₹14,858 |
| Retail(max) | 13 | 494 | ₹1,93,154 |
| sHNI(min) | 14 | 532 | ₹2,08,012 |
| sHNI(max) | 67 | 2,546 | ₹9,95,486 |
| sHNI(min) | 68 | 2,584 | ₹10,10,344 |
Senores Pharmaceuticals IPO Reservation
Senores Pharmaceuticals IPO reservation details show category-wise allocation of shares. Out of the total 1,48,12,723 shares, approximately 30% are reserved for QIB, 15% for NII, 10% for retail investors, and 45% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 66,65,725 (45%) | |
| QIB Shares Offered | 44,43,817 (30%) | |
| NII (HNI) Shares Offered | 22,21,909 (15%) | |
| bHNI > ₹10L | 15,18,605 (10.25%) | 2,854 |
| sHNI < ₹10L | 7,03,304 (4.75%) | 1,322 |
| Retail Shares Offered | 14,81,272 (10%) | 38,980 |
| Total Shares Offered | 1,48,12,723 (100%) |
Senores Pharmaceuticals IPO Analytics
Senores Pharmaceuticals IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Senores Pharmaceuticals IPO Subscription Status
Senores Pharmaceuticals IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 44,43,817 |
22,21,909
15,18,605
7,03,304
|
14,81,272 | 81,46,998 |
|
Day 1
20-12-24 05:00 PM
|
0.01 x |
1.67x
1.11x
2.80x
|
7.20 x | 1.78 x |
|
Day 2
23-12-24 05:00 PM
|
0.35 x |
24.48x
20.14x
33.15x
|
38.32 x | 13.87 x |
|
Day 3
24-12-24 05:00 PM
|
94.66 x |
96.11x
93.53x
101.27x
|
89.23 x | 93.41 x |
|
Total No. of Applications
|
bHNI | sHNI | Retail |
|---|---|---|---|
| 37,01,011 (Approx) | 20.12x | 106.99x | 77.82x |
Senores Pharmaceuticals Valuations
Earnings
- EPS Pre IPO
- ₹9.83/-
- EPS Post IPO
- ₹13.86/-
- P/E Pre IPO
- 39.77
- P/E Post IPO
- 28.21
Returns
- ROE
- 23.60%
- ROCE
- 11.73%
- RoNW
- 23.60%
- PAT Margin
- 15.25
Fundamentals
- Debt / Equity
- 1.07
- Price / Book
- 5.84
Senores Pharmaceuticals Financials( In Crs.)
| 31-Mar-24 | 31-Mar-23 | 31-Mar-22 | |
|---|---|---|---|
| Assets | 621.88 | 131.05 | 59.15 |
| Revenue | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 32.71 | 8.43 | 0.99 |
| Net Worth | 231.71 | 45.5 | 36.59 |
| Reserves & Surplus | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 248.38 | 60.76 | 14.21 |
Senores Pharmaceuticals Company & Offer Insights
About Senores Pharmaceuticals
Senores Pharmaceuticals is the world's leading research-driven pharmaceutical firm with a presence in several nations, engaged in the research and development, as well as manufacture of a myriad of pharmaceuticals products. The firm has thus built an independent niche in a regulated marketplace in US and Canada besides maintaining robust performance in emerging markets within 43 countries.
Senores Pharmaceuticals has strategically focused on specialty, underpenetrated, and complex pharmaceutical products and has emerged as the preferred partner for top-tier Indian and foreign pharmaceutical companies such as Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals, Dr. Reddy's Laboratories Inc., and Cipla USA Inc.
The company has capabilities in a variety of therapeutic areas and multiple dosage forms, from the manufacturing of critical care injectables and APIs. Senores Pharmaceuticals possesses a fast-growing portfolio with 182 products registered as of March 31, 2024, and a further 245 filings ongoing.
Senores Pharmaceuticals with 113 employees operating by working lean yet efficiently keeps the innovation, regulatory compliance as well as quality manufacturing along with high-value pharmaceutical solutions delivering. Its commitment to research development and partnerships makes it very key in advancing healthcare solution across global markets.
This IPO is going to be an exciting stage for the company, aiming at the strengthening of its position in the market, product development, and exploitation of growing opportunities within the global pharmaceutical sector.
Senores Pharmaceuticals Promoter(s)
Swapnil Jatinbhai Shah, Ashokkumar Vijaysinh Barot are the company's promoters of Senores Pharmaceuticals.
Senores Pharmaceuticals IPO Issue Objectives
- •
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(Havix), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility
- •
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- •
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary
- •
- Funding the working capital requirements of the Company;
- •
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (SPI)and Ratnatris Pharmaceutical Private Limited (Ratnatris), to fund their working capital requirements.
- •
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals IPO - Anchor Investors
Senores Pharmaceuticals IPO: Institutional investors invest Rs 261 crore via anchor book.
Domestic institutional investors like ICICI Prudential Mutual Fund, Aditya Birla Sun Life Insurance, Mahindra Manulife, Bank of India Mutual Fund, SBI General Insurance, Troo Capital, Meru Investment Fund and Edelweiss Life Insurance made investment in the company via anchor book.
Furthermore, Goldman Sachs, Societe Generale, Beacon Stone Capital, LC Pharos Multi Strategy Fund, Intergrated Global Strategies, and Fortune Hands Growth Fund also bought shares in the company via anchor book.
Senores Pharmaceuticals IPO - Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Ajanta Pharma Ltd. | 64.82 | 64.77 | 281.6 | 43.34 | 23.47 | 7.96 | Consolidated |
| Alembic Ltd. | 31.33 | 31.33 | 245.12 | 33.9 | 13.4 | 0.34 | Consolidated |
| Caplin Point Laboratories Ltd. | 60.79 | 59.9 | 309.03 | 40.84 | 21.69 | 4.26 | Consolidated |
| Gland Pharma Limited | 46.9 | 46.9 | 529.65 | 37.27 | 9.26 | 3.49 | Consolidated |
| Strides Pharma Science Ltd | -7.76 | -7.76 | 225.43 | N/A | -4.44 | 5.64 | Consolidated |
Notes:
- The P/E Ratio has been computed based on the closing market price of equity shares on December 13, 2024, divided by the Diluted EPS.
- Return on Net Worth (%) = Net profit after tax, as restated / Average shareholders' equity (including minority interest) as restated at year/period end.
- NAV is computed as the closing net worth (excluding minority interest) divided by the closing outstanding number of equity shares.
- Net worth means the aggregate value of the paid-up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation as at year/ period end, as per Restated Financial Statement of Assets and Liabilities of the Company.
Senores Pharmaceuticals IPO - Strengths and Risks
Senores Pharmaceuticals IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Senores Pharmaceuticals
+91-79-29999857
1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054
Registrar Contact Details
Frequently Asked Questions
Click any question to reveal the answer
Senores Pharmaceuticals IPO is a book-built IPO worth ₹582.11 crore. The price band is ₹372–₹391 per share. The IPO opens on Dec 20, 2024 and closes on Dec 24, 2024. It will be listed on BSE and NSE. Link Intime India Private Ltd is the registrar.
The price band of Senores Pharmaceuticals IPO is ₹372 to ₹391 per share.
The lot size of Senores Pharmaceuticals IPO is 38 shares.
The minimum investment for Senores Pharmaceuticals IPO is approximately ₹14,858 based on the upper price band .
Senores Pharmaceuticals IPO opens on Dec 20, 2024 and closes on Dec 24, 2024.
The allotment date of Senores Pharmaceuticals IPO is Dec 26, 2024.
Senores Pharmaceuticals IPO is expected to be listed on Dec 30, 2024, on BSE and NSE .
Senores Pharmaceuticals IPO listed on Dec 30, 2024. It was issued at ₹600.0(NSE) and is currently around ₹960.00 as on 14-May-2026 3:30 PM, which is approximately 145.5% versus issue price. The 52-week high is ₹990.55.
Based on listing and post-listing performance, Senores Pharmaceuticals IPO delivered around 145.5% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Senores Pharmaceuticals IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Senores Pharmaceuticals IPO valuation snapshot: P/E 28.21, EPS ₹13.86/-, P/B 5.84, RoNW 23.60%, and market cap N/A.
To apply for Senores Pharmaceuticals IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Senores Pharmaceuticals IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Senores Pharmaceuticals IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Senores Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Senores Pharmaceuticals IPO allotment status on IPO Ji for quick and easy access.